PHT-1
PT
Menu
Search

Sections

  • Home
  • News
  • Analysis
    • Features
    • Comment
    • Projects
  • Sectors
    • Clinical Trials
    • Drug Manufacturers
    • Therapy Area
      • Cardiovascular
      • Central Nervous System
      • Immunology
      • Infectious Disease
      • Oncology
      • Respiratory
  • Themes
    • Artificial Intelligence
    • Corporate Governance
    • Cloud
    • Cybersecurity
    • Environmental Sustainability
    • Internet of Things
    • Robotics
    • Social Responsibility
    • Covid-19
  • Insights
    • Deals
    • Jobs
    • Filings
    • Patents
    • Social Media
  • Companies
    • Company A-Z
    • Company Categories
    • Products & Services
    • Company Releases
    • White Papers
    • Videos
    • Buyer’s Guides
    • Partner Content
  • Pricing and Market Access
  • Events
  • Reports
  • Premium Insights
  • Excellence Awards
  • Magazine

GlobalData

  • About us
  • Advertise With Us
  • Contact Us
  • Our Marketing Solutions
  • GlobalData Reports
  • Visit GlobalData

From Our Partners

  • Transforming MedTech and Pharma using Software as a Medical Device (SaMD)
  • Accelerating Biopharmaceutical Innovation
  • Accelerating Clinical Trials
  • Precision medicine and digital health innovation for disease diagnosis, care and treatment
  • Enabling process intensification in biopharma manufacturing
  • Specialty drug launch strategy and operations
  • The next chapter of clinical trial services
  • Future Pharma Services
  • Putting quality first in the pharma supply chain
  • Enabling better biopharmaceutical manufacturing
  • Pharmaceutical Grade Silicone Manufacturer
  • Maximising molecule potential
  • News
  • Analysis

    Sections

    • Features
    • Comment
    • Projects

    Latest

    • Sentiment towards Brexit has worsened three years after UK left EU
    • US companies drive 2023 drug launches positioned for blockbuster success by 2028
    • Catalent CEO drops FY2023 revenue forecast by $450m after “disappointing” quarter
  • Sectors

    Sections

    • Clinical Trials
    • Drug Manufacturers
    • Therapy Area

    Latest

    • Fusion's Radiopharmaceutical Manufacturing Facility, Ontario, Canada
    • Janssen submits NDA to FDA for PAH combination therapy
    • Stealth and Pharmanovia partner for commercialisation of elamipretide
  • Themes

    Sections

    • Artificial Intelligence
    • Cloud
    • Corporate Governance
    • Cybersecurity
    • Environmental Sustainability
    • Internet of Things
    • Robotics
    • Social Responsibility
    • Covid-19

    Latest

    • XtalPi announces $250m AI drug discovery collaboration with Eli Lilly
    • University of Sydney will use AI to boost cancer drug research
    • Catalent CEO drops FY2023 revenue forecast by $450m after “disappointing” quarter
  • Insights

    Sections

    • Deals
    • Jobs
    • Filings
    • Patents
    • Social Media

    Latest

    • Who’s saying what? Microbiome mentions in company filings of pharmaceutical industry decreased by 30% in Q1 2023
    • Who’s saying what? Blockchain mentions in company filings of pharmaceutical industry increased by 17% in Q1 2023
    • Who’s saying what? Orphan Designated Drugs mentions in company filings of pharmaceutical industry decreased by 18% in Q1 2023
  • Companies

    Sections

    • Company A-Z
    • Company Categories
    • Products & Services
    • Company Releases
    • White Papers
    • Videos
    • Buyer’s Guides
    • Partner Content

    Latest

    • Medicines adherence: Overcoming pharma’s biggest barrier to treatment success
    • Untangling the Complexities of Cell and Gene Therapy Clinical Trials: A Supply Chain Perspective 
    • Untangling the Complexities of Cell and Gene Therapy Clinical Trials: A Supply Chain Perspective 
  • Events
  • Reports
  • Premium Insights
PT
  • Companies
Left
Right
  • Company A-Z
  • Company Categories
  • Products & Services
  • Company Releases
  • White Papers
  • Videos
  • Buyer’s Guides
  • Partner Content

Ypsomed

Subscribed

You have successfully subscribed and will receive the next available issues

Pen Injectors, Pen Needles and Auto-Injectors for Self-Injection

Ypsomed is the leading independent developer and manufacturer of user-friendly self-injection systems. To complement our innovative and reliable pen systems for the injection of insulin, hGH, FSH and PTH provides a complete range of dual-chamber pen and syringe-based auto-injector platforms for monodose injections.

Ypsomed unique 'click-on' pen needles and safety pen needles are compatible with our own and all other widely available pens. A broad-based technology platform and over 250 patent families mean Ypsomed can meet virtually all customer needs in the growing market for self-injection systems.

Website
www.ypsomed.com
Email Address
info@ypsomed.com
Address
Brunnmattstrasse 6,
Postfach,
3401 Burgdorf,
Switzerland
Phone
+41 34 424 41 11
Fax Number
+41 34 424 41 22
  • About us
  • Videos
  • Press Releases
  • Regional Offices

Videos

YpsoMate: the two-step autoinjector

Go for simplicity.

Press Releases

Romaco Provides First Siebler StripTabs Line to Ankur Drugs and Pharma

Romaco has developed the first Siebler StripTabs™ line for Indian contract manufacturer ANKUR Drugs and Pharma Ltd. The system's innovative design was specially created for the production and packaging of pharmaceutical film tablets. For the first time, this novel drug delivery sy

19 January 2010

Endress+Hauser’s Coriolis Mass Flow and Density Measurement for Life Sciences Industries

Complying with the stringent requirements, codes and standards ASME BPE, ISPE, FDA, EHEDG and 3-A, Promass P offers the enhanced performance of a bent tube meter and the drainability of a straight tube meter without any compromise. Now there is no need to trade-off between accuracy and drainabili

28 April 2009

Join Endress+Hauser at the 8th Annual World Drug Manufacturing Summit 2009

World Drug Manufacturing is now in its eighth year and will be taking place 2-4 December 2009 at Maritim ProArte, Berlin, Germany. Although the current economic crisis affects everyone, the drug manufacturing industry can continue to thrive through reducing the cost of goods, increasin

26 March 2009

Deltapilot is the Test Champion

The Contite measuring cell proves its unbeatable advantages At customers’ premises, our instruments are actually on the test bench day by day – Deltapilot S FMB70, however, has recently passed a special test. Developed for the requirements of the pharmaceutical and hygiene industry it s

5 January 2009

Reduced to Advantage – a Hygiene Probe in the Guided Radar Segment

Endress+Hauser expands the Levelflex M product line with the FMP43, a hygiene probe, especially developed for the high requirements of the pharmaceutical industry. The reduction to industry-specific requirements is the target – i.e. the reduction to the advantages. Main aspects are the hygiene

5 June 2008

Endress+Hauser Team Training on GAMP5

The core purpose of the Good Automation Manufacturing Practice (GAMP) is to meet to meet the 'fit for intended use' regulations concerning computerized systems as well as other current regulatory requirements. The motto could be: 'implementing the existing industrial good practice in the most eff

5 June 2008

Clean Room Monitoring

Since product quality is often affected by the environmental conditions in a clean room, it is essential to monitor critical parameters such as particle concentration,temperature, differential pressure and humidity. In addition air flow (speed and direction) and door interlocking must be contro

2 June 2008

Calibration Management Software: Compucal

Maintenance plannings and budgets, intervals between verifications tests or calibrations, managing the available resource and sub suppliers as well as their levels of training and providing information to the management are some examples of tasks which must be conducted in a compliant way in regu

7 June 2007

Improved Efficiency, Innovation and Compliance

Suppliers of equipment and services must be able to demonstrate their level of compliance to licensed pharma / biotech manufacturers of drugs, intermediates, active pharmaceutical ingredients, and biological products. Within the culture of Endress+Hauser, we understand that our contribution

18 April 2006
Address
Ypsomed AG
Brunnmattstrasse 6
Postfach
3401 Burgdorf
Switzerland

Email address
info@ypsomed.com
Phone
+41 34 424 41 11
Fax Number
+41 34 424 41 22
www.ypsomed.com
PharmaceuticalTechnology

The leading site for news and procurement in the pharmaceutical industry

  • About us
  • Advertise with us
  • License our content
  • Contact us
  • Editorial approach
  • Newsletters
  • Our marketing solutions
  • Privacy policy
  • Terms and conditions

Powered by Pharma Tech Logo

© Verdict Media Limited 2023

  • Lost Password Back ⟶
  • Login
  • Register
Lost Password?
Registration is disabled.